Cite

HARVARD Citation

    Murai, K. et al. (2018). Rapid reduction in BCR‐ABL1 transcript predicts deep molecular response in dasatinib‐treated chronic‐phase chronic myeloid leukaemia patients. European journal of haematology. pp. 27-35. [Online]. 
  
Back to record